Humanized Mouse Model Market - Size, Share, Overview and Future Forecast

According to the new market research report "Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) - Global Forecast", published by MarketsandMarkets™.

 

The Humanized Mouse Model Market is projected to reach USD 128.9 Million, at a CAGR of 9.9% during the forecast period.

 

The Humanized Rat Model Market is expected to reach USD 8.9 Million by 2022 from USD 5.9 Million in 2017, at a CAGR of 8.4% during the forecast period.

 

Market Dynamics:

 

Driver: Growing demand for personalized medicine

 

Personalized medicine is the process of developing tailored medicines to target individualized treatment and care based on personal and genetic variations. These medicines are designed through the use of animal models, particularly mice models. Immune-deficient models are transplanted with human tissues and the disease expressed is recorded. This is followed by treating the model with a whole series of drugs or gene therapies to find the most suitable treatment, thus generating suitable or personalized medicine for patients.

 

Currently, cancer is a major burden on the healthcare systems across geographies. By 2020, the direct/indirect cost of cancer is estimated to be USD 300 billion in the US. Several in vitro and in vivo strategies are being developed in an attempt to combat the rising prevalence of cancer and offer effective treatments to patients. One of the major developments in this regard is the emergence of humanized mouse and rat models as they have high predictive power for the efficacy of standard and novel anti-cancer therapeutics. Several research studies are being conducted to develop better mice models that can mimic the human genome and respond to a wide range of human diseases.

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

 

Humanized Mouse and Rat Model Market Segmentation in Detailed:

 

Based on type, the market is segmented into humanized mouse and humanized rat. The Humanized mouse model market is further segmented into cell-based and genetic based humanized mouse model. The genetic humanized mouse models segment accounted for the largest share of the market. The large share of this segment can be attributed to the wide use of genetic humanized mouse models in the analysis of compounds, biological efficacy and safety testing, study of drug metabolism and disposition, and investigation of immune system development and function.

 

 

Based on end-user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. The CROs segment is estimated to register the highest CAGR during the forecast period due to the growth in the number of pharmaceutical companies outsourcing their preclinical studies to CROs.

 

Worldwide Geographical Analysis:

 

 

The North American region is leading the humanized mouse models market is expected to account for the largest share of the market in 2017. Growth in this regional segment can primarily be attributed to growing biomedical research, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, increasing monoclonal antibody production in the US along with growing stem cell research, and government support for the development of protein drugs in Canada

 

Request Research Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955

 

Major Key Players Operating in Industry:

 

The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).